Ardipusilloside I, extracted from ARDISIA PUSILLA A.DC, effectively inhibits the progression of several cancers in animal models and is a potential anti-cancer drug candidate. However, the metabolism and pharmacokinetic characteristics of ardipusilloside I remain unknown. In this study, we developed a highly sensitive liquid chromatography-tandem MS method to determine the ardipusilloside I concentration in rat plasma using ginsenoside Re (whose structure is similar to ardipusilloside I) as the internal standard. After oral administration of ardipusilloside I, its four possible metabolites (M1, M2, M3, and M4, whose structures were determined by MS) were detected in the content from rat small intestine. In rat plasma, however, only M3 and M4 were detected after oral administration of ardipusilloside I. None of the metabolites were detected in plasma samples after intravenous administration of ardipusilloside I to rats. These results indicated that the metabolites, but not the drug itself, were absorbed into plasma after oral administration of ardipusilloside I to rats and that M3 and M4 may be responsible for the antitumor activity of orally administered ardipusilloside I in rat models of cancer.

Download full-text PDF

Source
http://dx.doi.org/10.1055/s-0031-1298238DOI Listing

Publication Analysis

Top Keywords

administration ardipusilloside
16
ardipusilloside rats
12
oral administration
12
ardipusilloside
10
metabolism pharmacokinetic
8
rat plasma
8
ardipusilloside metabolites
8
pharmacokinetic study
4
study ardipusilloside
4
rats ardipusilloside
4

Similar Publications

Aims: Ardipusilloside I (ADS-I), a triterpenoid saponin isolated from Ardisia pusilla A.DC (Myrsinaceae), has been recently tested for cancer treatment including brain cancer. However, the mechanism of its action remains elusive.

View Article and Find Full Text PDF

Ardipusilloside I, extracted from ARDISIA PUSILLA A.DC, effectively inhibits the progression of several cancers in animal models and is a potential anti-cancer drug candidate. However, the metabolism and pharmacokinetic characteristics of ardipusilloside I remain unknown.

View Article and Find Full Text PDF

[Inhibitory effect of ardipusilloside-I on Lewis pulmonary carcinoma and hepatocarcinoma SMMC-7721].

Zhong Yao Cai

July 2005

Faculty of Pharmacology of Medical College & Key Laboratory of Ministry of Education of Environment and Genes Related to Disease, Xi' an Jiaotong University, Xi' an 710061.

Objective: To study the antitumor effect of ardipusilloside-I (ADS-I) on Lewis pulmonary carcinoma and hepatocarcinoma SMMC-7721.

Methods: Lewis pulmonary metastasizing model was made by Sc. diluted 3-time 20 microl cancer cells in the right sole of C57BL/6 mice, after we treated the mice 14 days with ADS-I orally, cut the neoplasia-foot and weighed, we calculated the inhibitory rate in situ, then put the mice to death after being administrated 11 days continuously, counted the lung medtastasis colony and calculated the metastasis inhibitory rate; Human being hepatocarcinoma model was made by sc.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!